Amphastar Pharmaceuticals reported a strong first quarter with net revenues of $120.4 million and a GAAP net income of $24.3 million, driven by strong sales of recently launched products.
Net revenues reached $120.4 million.
GAAP net income was $24.3 million, or $0.47 per share.
Adjusted non-GAAP net income amounted to $24.6 million, or $0.47 per share.
Growth trend is expected to continue in 2022.
Amphastar is optimistic that its growth trend will continue in 2022.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance